Viewpoint examines funding sources for ophthalmic AI innovations, indicating potential impacts on future models.
This Viewpoint outlines the entities who have been funding ophthalmic artificial intelligence (AI) innovations in the past 5 years and considers what this shifting balance of power in funding might mean for the next wave of foundation AI models and clinical translation.
No takes yet. Share an insight, caveat, or question.
T. Y. Alvin Liu (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: